Loading...
Skip to Content

Pipelines

Anti IPD

Discovery
Early
Late
Pre-clinical
Early
Late
Clinical-trial
Phase 1
Phase 2
Phase 3
Marketing
authorization
ON GOING
Pneumococcal 13
Pneumococcal 20+

Anti IMD

Discovery
Early
Late
Pre-clinical
Early
Late
Clinical-trial
Phase 1
Phase 2
Phase 3
Marketing
authorization
ON GOING
Meningococcal Group ACWY
Meningococcal Group B L8 Endotoxoid (Concept for Safety Phase I)
Meningococcal Group B L7 Endotoxoid
(Nanostructured VS)
Meningococcal Pentavalent (A,B,C,W,Y)

Multidrug Resistance

Discovery
Early
Late
Pre-clinical
Early
Late
Clinical-trial
Phase 1
Phase 2
Phase 3
Marketing
authorization
Clostridium Difficile
- Escherichia Coli
- Salmonella Typhi
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
- Acinetobacter baumannii

Nanostructured Vector System for Viral subunit vaccines

Discovery
Early
Late
Pre-clinical
Early
Late
Clinical-trial
Phase 1
Phase 2
Phase 3
Marketing
authorization
- COV-2
- RSV
- Influenza
Developed by